The lower odds ratios for the breast and prostate cancer PRS in male BRCA1 and BRCA2 carriers, compared with the general population, may reflect a general attenuation of the effect sizes of common variants on genetic risk in the presence of a pathogenic variant in a high-risk gene (35,36). This evidence concerns the gene BRCA2 and prostate carcinoma.